Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA

Watchlist Manager
Kiniksa Pharmaceuticals Ltd Logo
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Watchlist
Price: 21.28 USD 0.9%
Market Cap: 1.5B USD
Have any thoughts about
Kiniksa Pharmaceuticals Ltd?
Write Note

Intrinsic Value

The intrinsic value of one KNSA stock under the Base Case scenario is 28.26 USD. Compared to the current market price of 21.28 USD, Kiniksa Pharmaceuticals Ltd is Undervalued by 25%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

KNSA Intrinsic Value
28.26 USD
Undervaluation 25%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Kiniksa Pharmaceuticals Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for KNSA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about KNSA?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Kiniksa Pharmaceuticals Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Kiniksa Pharmaceuticals Ltd

Provide an overview of the primary business activities
of Kiniksa Pharmaceuticals Ltd.

What unique competitive advantages
does Kiniksa Pharmaceuticals Ltd hold over its rivals?

What risks and challenges
does Kiniksa Pharmaceuticals Ltd face in the near future?

Has there been any significant insider trading activity
in Kiniksa Pharmaceuticals Ltd recently?

Summarize the latest earnings call
of Kiniksa Pharmaceuticals Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Kiniksa Pharmaceuticals Ltd.

Provide P/S
for Kiniksa Pharmaceuticals Ltd.

Provide P/E
for Kiniksa Pharmaceuticals Ltd.

Provide P/OCF
for Kiniksa Pharmaceuticals Ltd.

Provide P/FCFE
for Kiniksa Pharmaceuticals Ltd.

Provide P/B
for Kiniksa Pharmaceuticals Ltd.

Provide EV/S
for Kiniksa Pharmaceuticals Ltd.

Provide EV/GP
for Kiniksa Pharmaceuticals Ltd.

Provide EV/EBITDA
for Kiniksa Pharmaceuticals Ltd.

Provide EV/EBIT
for Kiniksa Pharmaceuticals Ltd.

Provide EV/OCF
for Kiniksa Pharmaceuticals Ltd.

Provide EV/FCFF
for Kiniksa Pharmaceuticals Ltd.

Provide EV/IC
for Kiniksa Pharmaceuticals Ltd.

Show me price targets
for Kiniksa Pharmaceuticals Ltd made by professional analysts.

What are the Revenue projections
for Kiniksa Pharmaceuticals Ltd?

How accurate were the past Revenue estimates
for Kiniksa Pharmaceuticals Ltd?

What are the Net Income projections
for Kiniksa Pharmaceuticals Ltd?

How accurate were the past Net Income estimates
for Kiniksa Pharmaceuticals Ltd?

What are the EPS projections
for Kiniksa Pharmaceuticals Ltd?

How accurate were the past EPS estimates
for Kiniksa Pharmaceuticals Ltd?

What are the EBIT projections
for Kiniksa Pharmaceuticals Ltd?

How accurate were the past EBIT estimates
for Kiniksa Pharmaceuticals Ltd?

Compare the revenue forecasts
for Kiniksa Pharmaceuticals Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Kiniksa Pharmaceuticals Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Kiniksa Pharmaceuticals Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Kiniksa Pharmaceuticals Ltd compared to its peers.

Compare the P/E ratios
of Kiniksa Pharmaceuticals Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Kiniksa Pharmaceuticals Ltd with its peers.

Analyze the financial leverage
of Kiniksa Pharmaceuticals Ltd compared to its main competitors.

Show all profitability ratios
for Kiniksa Pharmaceuticals Ltd.

Provide ROE
for Kiniksa Pharmaceuticals Ltd.

Provide ROA
for Kiniksa Pharmaceuticals Ltd.

Provide ROIC
for Kiniksa Pharmaceuticals Ltd.

Provide ROCE
for Kiniksa Pharmaceuticals Ltd.

Provide Gross Margin
for Kiniksa Pharmaceuticals Ltd.

Provide Operating Margin
for Kiniksa Pharmaceuticals Ltd.

Provide Net Margin
for Kiniksa Pharmaceuticals Ltd.

Provide FCF Margin
for Kiniksa Pharmaceuticals Ltd.

Show all solvency ratios
for Kiniksa Pharmaceuticals Ltd.

Provide D/E Ratio
for Kiniksa Pharmaceuticals Ltd.

Provide D/A Ratio
for Kiniksa Pharmaceuticals Ltd.

Provide Interest Coverage Ratio
for Kiniksa Pharmaceuticals Ltd.

Provide Altman Z-Score Ratio
for Kiniksa Pharmaceuticals Ltd.

Provide Quick Ratio
for Kiniksa Pharmaceuticals Ltd.

Provide Current Ratio
for Kiniksa Pharmaceuticals Ltd.

Provide Cash Ratio
for Kiniksa Pharmaceuticals Ltd.

What is the historical Revenue growth
over the last 5 years for Kiniksa Pharmaceuticals Ltd?

What is the historical Net Income growth
over the last 5 years for Kiniksa Pharmaceuticals Ltd?

What is the current Free Cash Flow
of Kiniksa Pharmaceuticals Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Kiniksa Pharmaceuticals Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Kiniksa Pharmaceuticals Ltd

Current Assets 301m
Cash & Short-Term Investments 218.8m
Receivables 20.5m
Other Current Assets 61.8m
Non-Current Assets 241.4m
PP&E 12.4m
Intangibles 16.8m
Other Non-Current Assets 212.3m
Current Liabilities 84.3m
Accounts Payable 7.4m
Accrued Liabilities 65.4m
Other Current Liabilities 11.5m
Non-Current Liabilities 23m
Other Non-Current Liabilities 23m
Efficiency

Earnings Waterfall
Kiniksa Pharmaceuticals Ltd

Revenue
384.1m USD
Cost of Revenue
-52.6m USD
Gross Profit
331.5m USD
Operating Expenses
-357.7m USD
Operating Income
-26.2m USD
Other Expenses
17.2m USD
Net Income
-9.1m USD

Free Cash Flow Analysis
Kiniksa Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

KNSA Profitability Score
Profitability Due Diligence

Kiniksa Pharmaceuticals Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
ROE is Increasing
45/100
Profitability
Score

Kiniksa Pharmaceuticals Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

KNSA Solvency Score
Solvency Due Diligence

Kiniksa Pharmaceuticals Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Short-Term Solvency
79/100
Solvency
Score

Kiniksa Pharmaceuticals Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KNSA Price Targets Summary
Kiniksa Pharmaceuticals Ltd

Wall Street analysts forecast KNSA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KNSA is 36.72 USD with a low forecast of 32.32 USD and a high forecast of 42 USD.

Lowest
Price Target
32.32 USD
52% Upside
Average
Price Target
36.72 USD
73% Upside
Highest
Price Target
42 USD
97% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for KNSA?

Click here to dive deeper.

Dividends

Kiniksa Pharmaceuticals Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for KNSA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

KNSA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Kiniksa Pharmaceuticals Ltd Logo
Kiniksa Pharmaceuticals Ltd

Country

Bermuda

Industry

Biotechnology

Market Cap

1.5B USD

Dividend Yield

0%

Description

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The firm is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s programs include Rilonacept, which is a protein for inhibiting interleukin-1 alpha and interleukin-1beta; Mavrilimumab, is a monoclonal antibody that antagonizes the signaling of granulocyte macrophage colony stimulating factor, or GM-CSF; KPL-716, is a monoclonal antibody that simultaneously inhibits the signaling of the cytokines interleukin-31, or IL-31, and oncostatin M, or OSM, by targeting their common receptor subunit, oncostatin M receptor beta, or OSMR beta; KPL-045 is a monoclonal antibody inhibitor of the CD30/CD30L interaction, a T-cell co-stimulatory receptor involved in activated T-memory cell function, and KPL-404, is a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity.

Contact

Hamilton
Clarendon House, 2 Church Street
+7814399100.0
www.kiniksa.com

IPO

2018-05-24

Employees

215

Officers

CEO & Chairman of the Board
Mr. Sanj K. Patel
Senior VP & COO
Mr. Eben Tessari
Senior VP & Chief Medical Officer
Dr. John F. Paolini FACC, M.D., Ph.D.
Senior VP & CFO
Mr. Mark Ragosa C.F.A.
Chief Accounting Officer & Group VP of Finance
Mr. Michael R. Megna CPA
Senior Vice President of Technical Operations
Ms. Mei Jang
Show More
Senior VP & Chief Compliance Officer
Mr. Chad Morin
SVP, General Counsel & Secretary
Ms. Madelyn Demsky Zeylikman
Executive Vice President of Corporate Affairs
Mr. Carsten Boess M.B.A.
Senior Vice President of Regulatory Affairs
Ms. Martina Struck Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one KNSA stock?

The intrinsic value of one KNSA stock under the Base Case scenario is 28.26 USD.

Is KNSA stock undervalued or overvalued?

Compared to the current market price of 21.28 USD, Kiniksa Pharmaceuticals Ltd is Undervalued by 25%.

Back to Top